SG11202001111QA - Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis - Google Patents

Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis

Info

Publication number
SG11202001111QA
SG11202001111QA SG11202001111QA SG11202001111QA SG11202001111QA SG 11202001111Q A SG11202001111Q A SG 11202001111QA SG 11202001111Q A SG11202001111Q A SG 11202001111QA SG 11202001111Q A SG11202001111Q A SG 11202001111QA SG 11202001111Q A SG11202001111Q A SG 11202001111QA
Authority
SG
Singapore
Prior art keywords
alcoholic
invasive diagnostic
fatty liver
liver fibrosis
liver diseases
Prior art date
Application number
SG11202001111QA
Inventor
Rémy Hanf
Geneviève Cordonnier
John Brozek
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of SG11202001111QA publication Critical patent/SG11202001111QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/178Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/08Hepato-biliairy disorders other than hepatitis
    • G01N2800/085Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
SG11202001111QA 2017-09-18 2018-09-14 Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis SG11202001111QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17306201 2017-09-18
PCT/EP2018/074975 WO2019053233A1 (en) 2017-09-18 2018-09-14 Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis

Publications (1)

Publication Number Publication Date
SG11202001111QA true SG11202001111QA (en) 2020-03-30

Family

ID=60001810

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202001111QA SG11202001111QA (en) 2017-09-18 2018-09-14 Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis

Country Status (14)

Country Link
US (1) US11519034B2 (en)
EP (1) EP3684954A1 (en)
JP (1) JP7424981B2 (en)
KR (1) KR20200051676A (en)
CN (1) CN111065748B (en)
AU (1) AU2018332318A1 (en)
BR (1) BR112020004439A2 (en)
CA (1) CA3071219A1 (en)
EA (1) EA202090715A1 (en)
IL (1) IL272465A (en)
MX (1) MX2020002532A (en)
PH (1) PH12020500354A1 (en)
SG (1) SG11202001111QA (en)
WO (1) WO2019053233A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201900005700A1 (en) * 2019-04-12 2020-10-12 Metadeq Ltd NEW MARKER OF PATHOLOGY AND ITS USES
CN114630660A (en) * 2019-10-28 2022-06-14 基恩菲特公司 Combination therapy with antioxidant properties
CN111549123B (en) * 2020-06-12 2022-10-21 中山大学附属第三医院 Detection kit for circular RNA 0089762 and application thereof
US20230296624A1 (en) * 2020-08-03 2023-09-21 Genfit Method for nash risk assessment
MX2023002308A (en) 2020-08-25 2023-07-11 Lilly Co Eli Polymorphs of an ssao inhibitor.
CN112712896B (en) * 2021-03-26 2023-03-07 深圳市绘云生物科技有限公司 Diagnosis device and computer system for detecting non-alcoholic fatty liver disease state of subject
WO2024010753A1 (en) * 2022-07-06 2024-01-11 Georgetown University Mirna biomarkers and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070065844A1 (en) * 2005-06-08 2007-03-22 Massachusetts Institute Of Technology Solution-based methods for RNA expression profiling
ES2527438T3 (en) * 2006-08-08 2015-01-26 Metabolon, Inc. Markers of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and methods of their use
FR2953220B1 (en) * 2009-12-01 2012-11-23 Oreal MICROARN SIGNATURE OF EPIDERMIC DIFFERENTIATION AND USES
US9221751B2 (en) * 2009-11-26 2015-12-29 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
WO2013166363A2 (en) * 2012-05-03 2013-11-07 The Johns Hopkins University Methods and compositions useful for diagnosing inflammatory bowel disease-associated neoplasia
WO2016196945A1 (en) * 2015-06-05 2016-12-08 Regulus Therapeutics Inc. Non-alcoholic fatty liver disease biomarkers
IL257680B2 (en) * 2015-09-14 2023-03-01 Genfit Methods for diagnosing and evaluating non-alcoholic steatohepatitis

Also Published As

Publication number Publication date
BR112020004439A2 (en) 2020-10-06
EP3684954A1 (en) 2020-07-29
CN111065748A (en) 2020-04-24
IL272465A (en) 2020-03-31
JP7424981B2 (en) 2024-01-30
EA202090715A1 (en) 2020-07-15
WO2019053233A1 (en) 2019-03-21
CA3071219A1 (en) 2019-03-21
KR20200051676A (en) 2020-05-13
PH12020500354A1 (en) 2021-01-25
MX2020002532A (en) 2020-07-20
US20200216901A1 (en) 2020-07-09
CN111065748B (en) 2024-04-09
JP2021502109A (en) 2021-01-28
AU2018332318A1 (en) 2020-02-20
US11519034B2 (en) 2022-12-06

Similar Documents

Publication Publication Date Title
IL272869A (en) Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
IL272465A (en) Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
ZA201807083B (en) Non-invasive diagnostic of non-alcoholic steatohepatitis
EP3454745A4 (en) Diagnosis tailoring of health and disease
HK1249847A1 (en) Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
EP3426135A4 (en) Non-invasive detection of skin disease
ZA201805634B (en) Conjugate of therapeutic enzymes
EP3710831A4 (en) Markers for the diagnosis and treatment of non-alcoholic steatohepatitis (nash) and advanced liver fibrosis
IL268502A (en) Triplet combination formulations and methods of treating or reducing the risk of cardiovascular disease
IL275188A (en) Peptides for treatment and prevention of nonalcoholic fatty liver disease and fibrosis
IL272937A (en) Compositions and methods for the treatment of fibrotic diseases
EP3518918A4 (en) Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis
EP3781158A4 (en) Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
EP3362053A4 (en) Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
HK1250205A1 (en) Human milk compositions and methods of making and using same
IL271236A (en) Licofligozin for the treatment of non-alcoholic steatohepatitis
GB201710822D0 (en) Methods and medical uses relating to the treatment of hypoglycaemia
EP3740592A4 (en) Methods and compositions for the treatment of vascular disease
EP3459524A4 (en) Human body cleaning agent and preparation method therefor
EP3679930A4 (en) Therapeutic agent for fatty liver diseases and therapeutic agent for adiposity
EP3716975A4 (en) Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis
EP3718552A4 (en) Combination drug suitable for treatment and prevention of non-alcoholic fatty liver disease (naflad) and/or non-alcoholic steatohepatitis (nash), and/or hepatic steatosis
EP3599984A4 (en) Endoscopes and methods of use
EP3846843A4 (en) Compositions and methods for the treatment of heart disease
EP3615003A4 (en) Diagnosis and treatment of vitiligo